<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00984633</url>
  </required_header>
  <id_info>
    <org_study_id>P05976</org_study_id>
    <secondary_id>71102</secondary_id>
    <nct_id>NCT00984633</nct_id>
  </id_info>
  <brief_title>Study of Efficacy, Pharmacokinetics, and Safety of Bolus Maintenance Doses of Org 9426 (Study P05976)(COMPLETED)</brief_title>
  <official_title>Study of Efficacy, Pharmacokinetics, and Safety of Bolus Maintenance Doses of Org 9426 Following a Single Intubating Dose in Adult Subjects Undergoing Operation Under Sevoflurane or Propofol Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, pharmacokinetics, and safety of Org
      9426 in maintenance of muscle relaxation in adult subjects undergoing general elective
      surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical duration of 2 doses of Org 9426 in maintenance of muscle relaxation</measure>
    <time_frame>Time from intubating dose to bolus maintenance dose</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Muscle Relaxation</condition>
  <arm_group>
    <arm_group_label>0.6 mg/kg intubation dose + sevoflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9 mg/kg intubation dose + sevoflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.6 mg/kg intubation dose + propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9 mg/kg intubation dose + propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium bromide (Org 9426)</intervention_name>
    <description>0.6 mg/kg injection intubation dose</description>
    <arm_group_label>0.6 mg/kg intubation dose + sevoflurane</arm_group_label>
    <arm_group_label>0.6 mg/kg intubation dose + propofol</arm_group_label>
    <other_name>SCH 900085</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium bromide (Org 9426)</intervention_name>
    <description>0.9 mg/kg injection intubation dose</description>
    <arm_group_label>0.9 mg/kg intubation dose + sevoflurane</arm_group_label>
    <arm_group_label>0.9 mg/kg intubation dose + propofol</arm_group_label>
    <other_name>SCH 900085</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>0.5-2.0% intravenous maintenance anesthesia</description>
    <arm_group_label>0.6 mg/kg intubation dose + sevoflurane</arm_group_label>
    <arm_group_label>0.9 mg/kg intubation dose + sevoflurane</arm_group_label>
    <other_name>Sevofrane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>4-10 mg/kg/hr maintenance anesthesia</description>
    <arm_group_label>0.6 mg/kg intubation dose + propofol</arm_group_label>
    <arm_group_label>0.9 mg/kg intubation dose + propofol</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects at least 20 but under 65 years of age.

          -  Subjects of asa class 1, 2 or 3 for general elective surgery.

          -  Subjects who are not considered to be pregnant.

          -  Subjects scheduled for elective surgery under sevoflurane or propofol anesthesia, with
             anticipated duration of surgery of about 1.5-3 hours.

          -  Subjects with normal laboratory values for serum electrolytes (Na+, K+, Cl-), BUN,
             creatinine, total bilirubin, ALP, ALAT and ASAT as judged by the investigator or the
             sub-investigator.

          -  Subjects who received an explanation of the trial and agreed informed consent in
             writing to participate in the trial in advance.

        Exclusion Criteria:

          -  Subjects with renal dysfunction as a complication or in the history.

          -  Subjects with serum creatinine level greater than 1.6 mg/dL.

          -  Subjects with severe hepatic dysfunction as a complication or in the history.

          -  Subjects with known significant metabolic or neuromuscular disorders.

          -  Subjects with showing dyspnea, airway obstruction or bronchial asthma.

          -  Subjects with a history of hypersensitivity to pancuronium bromide, vecuronium bromide
             or bromine.

          -  Subjects with atopic diseases.

          -  Subjects who have developed any systemic allergic symptoms.

          -  Subjects receiving antihistamines and antiallergic agents for 1 month or more.

          -  Subjects receiving any of the following drugs known to affect on the action of
             neuromuscular blocking agents on surgery day: calcium antagonists; anticonvulsants;
             aminoglycoside antibiotics; polypeptide antibiotics; or metronidazole.

          -  Subjects under hypothermic anesthesia.

          -  Subjects who participated as research subjects in another trial within the last 6
             months or is now participating in other trials.

          -  Other subjects judged to be ineligible as subjects in this trial by the discretion of
             the investigator or the sub-investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2009</study_first_submitted>
  <study_first_submitted_qc>September 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2009</study_first_posted>
  <last_update_submitted>May 11, 2015</last_update_submitted>
  <last_update_submitted_qc>May 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuromuscular Blocking Agents</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

